{"topic":{"0":"Boceprevir","1":"Boceprevir","2":"Boceprevir","3":"Boceprevir","4":"Boceprevir","5":"Boceprevir","6":"Boceprevir","7":"Boceprevir","8":"Boceprevir","9":"Boceprevir","10":"Boceprevir","11":"Boceprevir","12":"Boceprevir"},"dialog_lvl":{"0":"model","1":"model","2":"model","3":"model","4":"model","5":"model","6":"model","7":"model","8":"model","9":"model","10":"model","11":"model","12":"model"},"role":{"0":"Explainer","1":"Explainee","2":"Explainer","3":"Explainee","4":"Explainer","5":"Explainee","6":"Explainer","7":"Explainee","8":"Explainer","9":"Explainee","10":"Explainer","11":"Explainee","12":"Explainer"},"turn_num_tokens":{"0":12,"1":6,"2":9,"3":9,"4":27,"5":7,"6":20,"7":7,"8":35,"9":9,"10":19,"11":5,"12":7},"turn":{"0":"Hi, I'm your automated assistant. I can answer your questions about Boceprevir.","1":"What is the dosage of Boceprevir?","2":"400 to 1000 mg\/day) and boceprevir for 48 weeks.","3":"Are there any other interesting aspects about this article?","4":"The patients enrolled in the SPRINT-1 study were among the most difficult to treat, and were exclusively those with genotype 1. (The patients were all treatment naive.)","5":"Why were they more difficult to treat?","6":"Additionally, many of the patients had other difficult-to-treat indices, including cirrhosis (6\u20139%), high viral load (90%), and African-American ancestry (14\u201317%).","7":"Did it successfuly treat the Hepatitis C?","8":"An SVR after 24 weeks off therapy of 75% was achieved in the group treated for 48 weeks with four weeks of lead-in therapy with peginterferon alfa-2b plus ribavirin followed by the addition of boceprivir.","9":"What did the other 5% go on to do?","10":"This represents a near doubling of the rate of SVR compared to standard therapy without boceprevir in this group.","11":"Was there any side effects?","12":"Anemia was the most common adverse event."}}